FIREFLY NEUROSCIENCE, INC. (AIFF): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the board of directors (the “Board”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Comp
How this was made
The 30-second read
Why it matters
While the news is new, the company’s small size limits material impact; investors may watch for any subsequent guidance changes.
Market read
Primary disclosure of executive change; limited trading relevance for a micro‑cap.
What to watch
Potential impact of the new CAO's prior experience at Genvid and Finastra on financial controls.
Background
The filing is a routine SEC 8‑K disclosure of executive turnover for Firefly Neuroscience, Inc.
Ticker impact
SEC Form 8‑K reports termination of CFO Paul Krzywicki and appointment of Jessica Paz as Chief Accounting Officer.
Potential modest price movement as market digests leadership change.
The filing is a primary disclosure but involves a micro‑cap with limited scale; impact is likely limited to short‑term speculation.
Market effects
Minimal effect on the broader neuroscience/biotech sector.
Limited to U.S. micro‑cap investors.
Low global relevance.
Counterpoint
The leadership change could signal deeper operational issues not yet reflected in the price.
Key entities
- companyFirefly Neuroscience, Inc.
Micro‑cap neuroscience firm filing the 8‑K.
- personPaul Krzywicki
Outgoing Chief Financial Officer.
- personJessica Paz
Newly appointed Chief Accounting Officer.
